The KCTD1 Knockout NCI-H1975 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population in which the endogenous KCTD1 gene is disrupted in the NCI-H1975 human lung adenocarcinoma epithelial cell line. This genetically heterogeneous pool allows robust loss-of-function studies while mitigating clonal selection artifacts, making it ideal for investigating KCTD1-dependent phenotypes in a non-small cell lung cancer context.
NCI-H1975 is an established non-small cell lung cancer model derived from the pleural effusion of a non-smoking female with lung adenocarcinoma. The cell line carries activating EGFR L858R and T790M mutations, which confer sensitivity to third-generation EGFR inhibitors such as osimertinib while rendering it resistant to first-generation agents like erlotinib and gefitinib. NCI-H1975 is wild-type for KRAS and TP53, providing a well-defined genetic background for dissecting tumor-suppressive pathways and drug response mechanisms.
KCTD1 functions as a substrate-specific adaptor for the CUL3-RBX1 E3 ubiquitin ligase complex, mediating polyubiquitination and subsequent proteasomal degradation of CTNNB1 (??-catenin), thereby attenuating Wnt/??-catenin transcriptional output. Beyond ubiquitination, KCTD1 directly binds the transcription factor TFAP2A and represses its target genes, linking TP53-dependent stress signals??KCTD1 is transcriptionally upregulated by TP53??to inhibition of Wnt effectors such as MYC and CCND1. This dual mechanism integrates proteasomal degradation and transcriptional repression, with key molecular interactions involving CUL3, CTNNB1, TFAP2A, and RBX1.
In the context of EGFR-mutant NCI-H1975 cells, disruption of KCTD1 may enhance Wnt/??-catenin signaling, potentially impacting processes such as epithelial-mesenchymal transition, cancer stem cell maintenance, or acquired resistance to EGFR tyrosine kinase inhibitors. The wild-type TP53 status of NCI-H1975 enables precise investigation of the TP53-KCTD1 tumor-suppressive axis and its role in DNA damage responses and modulation of drug sensitivity. This knockout model thus serves as a valuable platform for identifying synthetic vulnerabilities and elucidating resistance mechanisms in EGFR-driven NSCLC.
The polyclonal knockout cells are suitable for a variety of functional assays, including Western blotting and RT-qPCR for target validation, TOPFlash/FOPFlash reporter assays to measure Wnt transcriptional activity, co-immunoprecipitation and ubiquitination assays to study protein interactions and post-translational modification, cell viability and apoptosis assays to assess drug responses, transwell migration and invasion assays to evaluate metastatic potential, immunofluorescence for ??-catenin localization, and ChIP-qPCR for TFAP2A target gene occupancy. Key applications involve Wnt pathway interrogation in EGFR-mutant NSCLC, synthetic lethality screens with EGFR inhibitors, and mechanistic studies of drug resistance. For further details or custom inquiries, please contact Ascent Research.
